Home / Current Issue / Paper 1716192
Interleukin-8 Expression Under Highly Effective Host Immunological Control of HIV-1 Disease Progression
Subject area: Science,Engineering and Technology · Area of research: Medical Sciences
DOI: https://doi.org/10.64388/IREV9I10-1716192
Abstract
Background: Interleukin-8 (IL-8) is a pro-inflammatory chemokine involved in neutrophil recruitment and immune activation and has been implicated in HIV-1–associated inflammation and disease progression. Despite effective highly active antiretroviral therapy (HAART), residual immune activation persists in many people living with HIV, and the role of IL-8 across different stages of infection and treatment remains incompletely understood, particularly in sub-Saharan Africa. Methods: This cross-sectional study enrolled 40 participants in Osogbo, South-Western Nigeria, comprising HIV-negative controls (n=10), HAART-naïve HIV-positive individuals (OFF-HAART, n=10), HAART-treated individuals (ON-HAART, n=10), and AIDS progressors (n=10). Serum IL-8 levels were quantified using enzyme-linked immunosorbent assay, while CD4+ T-cell counts were determined by flow cytometry. Viral load, hematological indices, and selected biochemical parameters were also assessed. Associations between IL-8, immunological markers, and socio-demographic variables were analyzed using correlation and comparative statistics. Results: Interleukin-8 (IL-8) levels showed a downward trend from HIV-negative subjects (175.89 ± 84.58 pg/mL) and OFF-HAART individuals (211.14 ± 64.55 pg/mL) to ON-HAART participants (125.08 ± 39.73 pg/mL), with the lowest levels observed in AIDS progressors (11.40 ± 1.14 pg/mL), although this trend did not reach statistical significance (p = 0.088). CD4⁺ T-cell counts differed significantly across groups (p < 0.001), with marked depletion in OFF-HAART subjects (166.10 ± 41.40 cells/µL) and partial immune reconstitution in ON-HAART individuals (395.20 ± 61.69 cells/µL). Among AIDS progressors, longer infection duration was significantly associated with higher IL-8 expression (χ² = 6.667, p = 0.010). Conclusion: Elevated IL-8 is linked to impaired immune status and disease progression in HIV-1 infection, while reduced IL-8 accompanies immune recovery and advanced disease stages. IL-8 may serve as a useful biomarker of immune dysregulation and progression across HIV disease states, supporting its potential role in monitoring inflammation alongside conventional immunological markers.
References
[1] Balestre, E., Eholié, S. P., Lokossue, A., Sow, P. S., Charurat, M., Minga, A., Drabo, J., Dabis, F., Ekouevi, D. K., & Thiébaut, R. (2012). Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1- infected adults in West Africa. AIDS (London, England), 26(8), 951 –957. https:// 4
[2] Deeks, S. G., Tracy, R., & Douek, D. C. (2013). Systemic effects of inflammation on health during chronic HIV infection. Immunity, 39(4), 633–645. https://
[3] Ellwanger, J. H., Valverde-Villegas, J. M., Kaminski, V. de L., de Medeiros, R. M., Almeida, S. E. de M., Santos, B. R., de Melo, M. G., Hackenhaar, F. S., & Chies, J. A. B. (2020). Increased IL-8 levels in HIV-infected individuals who initiated ART with CD4+ T cell counts <350 cells/mm3 – A potential hallmark of chronic inflammation. Microbes and Infection, 22(9), 474–480. https://
[4] Gunawan, C. K., Sumarpo, A., & Indrati, A. R. (2026). Immune Dysregulation in HIV-TB Co- Infection: Role of Cytokines and T Cell Biomarkers—A Narrative Review. Pathogens, 15(1), 51. https://
[5] Love, M., Behrens-Bradley, N., Ahmad, A., Wertheimer, A., Klotz, S., & Ahmad, N. (2024). Plasma Levels of Secreted Cytokines in Virologically Controlled HIV-Infected Aging Adult Individuals on Long-Term Antiretroviral Therapy. Viral Immunology, 37(4), 202–215. https://
[6] Manaye, G. A., Abateneh, D. D., Kebede, K. M., & Belay, A. S. (2020). Immunological Response During HAART and Determinants of Current CD4+ T-Cell Count Among HIV/AIDS Patients Attending University of Gondar Referral Hospital, Northwest Ethiopia. HIV/AIDS (Auckland, N.Z.), 12, 295–306. https://
[7] Means, A. R., Risher, K. A., Ujeneza, E. L., Maposa, I., Nondi, J., & Bellan, S. E. (2016). Impact of Age and Sex on CD4+ Cell Count Trajectories following Treatment Initiation: An Analysis of the Tanzanian HIV Treatment Database. PLoS ONE, 11(10), e0164148. https://
[8] Mtshali, A., Ngcapu, S., Mindel, A., Garrett, N., & Liebenberg, L. (2021). HIV susceptibility in women: The roles of genital inflammation, sexually transmitted infections and the genital microbiome. Journal of Reproductive Immunology, 145, 103291. https://
[9] Mu, W., Patankar, V., Kitchen, S., & Zhen, A. (2024). Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection. Viruses, 16(2), 219. https://
[10] Obare, L. M., Temu, T., Mallal, S. A., & Wanjalla, C. N. (2024). Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease. Circulation Research, 134(11), 1515 –1545. https:// 891
[11] Palella, F. J., Baker, R. K., Moorman, A. C., Chmiel, J. S., Wood, K. C., Brooks, J. T., Holmberg, S. D., & HIV Outpatient Study Investigators. (2006). Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. Journal of Acquired Immune Deficiency Syndromes, 43(1), 27–34. https:// 4.16
[12] Santinelli, L., Ceccarelli, G., Borrazzo, C., Innocenti, G. P., Frasca, F., Cavallari, E. N., Celani, L., Nonne, C., Mastroianni, C. M., & d’Ettorre, G. (2020). Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients. Biology of Sex Differences, 11(1), 23. https://
[13] Teer, E., Mukonowenzou, N. C., & Essop, M. F. (2025). HIV, Inflammation, and Immunometabolism: A Model of the Inflammatory Theory of Disease. Viruses, 17(6), 839. https://
[14] UNIAD. (2025). Global HIV & AIDS statistics—Fact sheet | UNAIDS . https://www.unaids.org/en/resources/fact-sheet
[15] Xiong, X., Liao, X., Qiu, S., Xu, H., Zhang, S., Wang, S., Ai, J., & Yang, L. (2022). CXCL8 in Tumor Biology and Its Implications for Clinical Translation. Frontiers in Molecular Biosciences, 9. https://
How to cite this paper
@article{1716192,
author = {Tirimisiyu Alani Ogunola, Adesola Oyekunle Oyekale, Omolade Abiodun Felix; Adegoke Adekemi Omolola, Ahmed Ibrahim Oluwaseun; Ridwan Olanrewaju Ogunola, Ibraheem Olawale Ogunola; Lawal Lukmon Abiodun},
title = {Interleukin-8 Expression Under Highly Effective Host Immunological Control of HIV-1 Disease Progression},
journal = {Iconic Research And Engineering Journals},
year = {2026},
volume = {9},
number = {10},
pages = {1030-1041},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1716192.pdf},
abstract = {Background: Interleukin-8 (IL-8) is a pro-inflammatory chemokine involved in neutrophil recruitment and immune activation and has been implicated in HIV-1–associated inflammation and disease progression. Despite effective highly active antiretroviral therapy (HAART), residual immune activation persists in many people living with HIV, and the role of IL-8 across different stages of infection and treatment remains incompletely understood, particularly in sub-Saharan Africa.
Methods: This cross-sectional study enrolled 40 participants in Osogbo, South-Western Nigeria, comprising HIV-negative controls (n=10), HAART-naïve HIV-positive individuals (OFF-HAART, n=10), HAART-treated individuals (ON-HAART, n=10), and AIDS progressors (n=10). Serum IL-8 levels were quantified using enzyme-linked immunosorbent assay, while CD4+ T-cell counts were determined by flow cytometry. Viral load, hematological indices, and selected biochemical parameters were also assessed. Associations between IL-8, immunological markers, and socio-demographic variables were analyzed using correlation and comparative statistics.
Results: Interleukin-8 (IL-8) levels showed a downward trend from HIV-negative subjects (175.89 ± 84.58 pg/mL) and OFF-HAART individuals (211.14 ± 64.55 pg/mL) to ON-HAART participants (125.08 ± 39.73 pg/mL), with the lowest levels observed in AIDS progressors (11.40 ± 1.14 pg/mL), although this trend did not reach statistical significance (p = 0.088). CD4⁺ T-cell counts differed significantly across groups (p < 0.001), with marked depletion in OFF-HAART subjects (166.10 ± 41.40 cells/µL) and partial immune reconstitution in ON-HAART individuals (395.20 ± 61.69 cells/µL). Among AIDS progressors, longer infection duration was significantly associated with higher IL-8 expression (χ² = 6.667, p = 0.010).
Conclusion: Elevated IL-8 is linked to impaired immune status and disease progression in HIV-1 infection, while reduced IL-8 accompanies immune recovery and advanced disease stages. IL-8 may serve as a useful biomarker of immune dysregulation and progression across HIV disease states, supporting its potential role in monitoring inflammation alongside conventional immunological markers.},
month = {April},
doi = {https://doi.org/10.64388/IREV9I10-1716192}
}